Gita Ramjee1, Handan Wand. 1. HIV Prevention Research Unit, Medical Research Council, 123 Jan Hofmeyr Road, Westville, Durban, 3630, South Africa. Gita.Ramjee@mrc.ac.za
Abstract
OBJECTIVE: To estimate the potential impact of using hormonal contraceptives on rates of infection with human immunodeficiency virus type 1 (HIV-1) and pregnancy by theoretically removing the use of hormonal contraceptives from a study population. METHODS: A prospective cohort study included 3704 HIV-negative women who were enrolled in two biomedical trials that tested two vaginal microbicides (PRO 2000 and Carraguard®) for the prevention of HIV-1 in Durban, South Africa, in 2004-2009. Cox proportional hazards regression models along with partial population attributable risks (PARs) and their 95% confidence intervals (CIs) were calculated to assess the relative population-level impact of the use of hormonal contraceptives on HIV-1 seroconversion rates and on pregnancy rates. FINDINGS: Women who reported using hormonal contraceptives at enrolment in the trial had a higher risk of HIV-1 seroconversion (adjusted hazards ratio: 1.24; 95% CI: 0.97-1.58) than women who reported using other types of contraceptives at enrolment. At the population level, the use of hormonal contraceptives (pills or injectables) at baseline and during study follow-up accounted for approximately 20% (95% CI: 16-22) of HIV-1 seroconversions. However, the partial PAR indicated a relative impact of 12% (95% CI: 9.0-15.7). On the other hand, 72% (95% CI: 66-77) of the pregnancies could have been avoided if all women had used hormonal contraceptives. CONCLUSION: Women using hormonal contraceptives need comprehensive counselling on simultaneous prevention of HIV-1 infection.
OBJECTIVE: To estimate the potential impact of using hormonal contraceptives on rates of infection with human immunodeficiency virus type 1 (HIV-1) and pregnancy by theoretically removing the use of hormonal contraceptives from a study population. METHODS: A prospective cohort study included 3704 HIV-negative women who were enrolled in two biomedical trials that tested two vaginal microbicides (PRO 2000 and Carraguard®) for the prevention of HIV-1 in Durban, South Africa, in 2004-2009. Cox proportional hazards regression models along with partial population attributable risks (PARs) and their 95% confidence intervals (CIs) were calculated to assess the relative population-level impact of the use of hormonal contraceptives on HIV-1 seroconversion rates and on pregnancy rates. FINDINGS:Women who reported using hormonal contraceptives at enrolment in the trial had a higher risk of HIV-1 seroconversion (adjusted hazards ratio: 1.24; 95% CI: 0.97-1.58) than women who reported using other types of contraceptives at enrolment. At the population level, the use of hormonal contraceptives (pills or injectables) at baseline and during study follow-up accounted for approximately 20% (95% CI: 16-22) of HIV-1 seroconversions. However, the partial PAR indicated a relative impact of 12% (95% CI: 9.0-15.7). On the other hand, 72% (95% CI: 66-77) of the pregnancies could have been avoided if all women had used hormonal contraceptives. CONCLUSION:Women using hormonal contraceptives need comprehensive counselling on simultaneous prevention of HIV-1 infection.
Authors: S B Mostad; J Overbaugh; D M DeVange; M J Welch; B Chohan; K Mandaliya; P Nyange; H L Martin; J Ndinya-Achola; J J Bwayo; J K Kreiss Journal: Lancet Date: 1997-09-27 Impact factor: 79.321
Authors: Camaryn E Chrisman; Kathryn M Curtis; Anshu P Mohllajee; Mary E Gaffield; Herbert B Peterson Journal: Contraception Date: 2005-10-21 Impact factor: 3.375
Authors: H L Martin; P M Nyange; B A Richardson; L Lavreys; K Mandaliya; D J Jackson; J O Ndinya-Achola; J Kreiss Journal: J Infect Dis Date: 1998-10 Impact factor: 5.226
Authors: Mohammed Kiddugavu; Fred Makumbi; Maria J Wawer; David Serwadda; Nelson K Sewankambo; Fred Wabwire-Mangen; Tom Lutalo; Mary Meehan; Ronald H Gray Journal: AIDS Date: 2003-01-24 Impact factor: 4.177
Authors: Agnes Ssali; Stella Namukwaya; Leonard Bufumbo; Janet Seeley; David G Lalloo; Anatoli Kamali; Rosalind Parkes-Ratanshi Journal: PLoS One Date: 2013-09-10 Impact factor: 3.240